Cargando…

Corneal Refractive Surgery Considerations in Patients on Dupilumab

Dupilumab is a biologic approved by the United States Food and Drug Administration (US FDA) for the treatment of atopic dermatitis. While it is an effective medication for eczema, ocular side effects are common in patients receiving dupilumab therapy. Greater consideration is needed when evaluating...

Descripción completa

Detalles Bibliográficos
Autores principales: Moshirfar, Majid, Seitz, Tanner, Ply, Brianna, Ronquillo, Yasmyne C., Hoopes, Phillip C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225227/
https://www.ncbi.nlm.nih.gov/pubmed/35743344
http://dx.doi.org/10.3390/jcm11123273
_version_ 1784733568538247168
author Moshirfar, Majid
Seitz, Tanner
Ply, Brianna
Ronquillo, Yasmyne C.
Hoopes, Phillip C.
author_facet Moshirfar, Majid
Seitz, Tanner
Ply, Brianna
Ronquillo, Yasmyne C.
Hoopes, Phillip C.
author_sort Moshirfar, Majid
collection PubMed
description Dupilumab is a biologic approved by the United States Food and Drug Administration (US FDA) for the treatment of atopic dermatitis. While it is an effective medication for eczema, ocular side effects are common in patients receiving dupilumab therapy. Greater consideration is needed when evaluating these individuals for corneal refractive surgery. Dupilumab patients may suffer from atopy, a condition that also merits consideration in those desiring refractive surgery. Additional testing and careful consideration are needed, as these patients have an increased risk of dry eye syndrome, keratoconus, cataracts, diffuse lamellar keratitis, viral keratitis, and perioperative infection. This commentary discusses the current understanding of dupilumab ocular side effects and investigates factors to consider when evaluating these patients for corneal refractive surgery.
format Online
Article
Text
id pubmed-9225227
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92252272022-06-24 Corneal Refractive Surgery Considerations in Patients on Dupilumab Moshirfar, Majid Seitz, Tanner Ply, Brianna Ronquillo, Yasmyne C. Hoopes, Phillip C. J Clin Med Viewpoint Dupilumab is a biologic approved by the United States Food and Drug Administration (US FDA) for the treatment of atopic dermatitis. While it is an effective medication for eczema, ocular side effects are common in patients receiving dupilumab therapy. Greater consideration is needed when evaluating these individuals for corneal refractive surgery. Dupilumab patients may suffer from atopy, a condition that also merits consideration in those desiring refractive surgery. Additional testing and careful consideration are needed, as these patients have an increased risk of dry eye syndrome, keratoconus, cataracts, diffuse lamellar keratitis, viral keratitis, and perioperative infection. This commentary discusses the current understanding of dupilumab ocular side effects and investigates factors to consider when evaluating these patients for corneal refractive surgery. MDPI 2022-06-08 /pmc/articles/PMC9225227/ /pubmed/35743344 http://dx.doi.org/10.3390/jcm11123273 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Viewpoint
Moshirfar, Majid
Seitz, Tanner
Ply, Brianna
Ronquillo, Yasmyne C.
Hoopes, Phillip C.
Corneal Refractive Surgery Considerations in Patients on Dupilumab
title Corneal Refractive Surgery Considerations in Patients on Dupilumab
title_full Corneal Refractive Surgery Considerations in Patients on Dupilumab
title_fullStr Corneal Refractive Surgery Considerations in Patients on Dupilumab
title_full_unstemmed Corneal Refractive Surgery Considerations in Patients on Dupilumab
title_short Corneal Refractive Surgery Considerations in Patients on Dupilumab
title_sort corneal refractive surgery considerations in patients on dupilumab
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225227/
https://www.ncbi.nlm.nih.gov/pubmed/35743344
http://dx.doi.org/10.3390/jcm11123273
work_keys_str_mv AT moshirfarmajid cornealrefractivesurgeryconsiderationsinpatientsondupilumab
AT seitztanner cornealrefractivesurgeryconsiderationsinpatientsondupilumab
AT plybrianna cornealrefractivesurgeryconsiderationsinpatientsondupilumab
AT ronquilloyasmynec cornealrefractivesurgeryconsiderationsinpatientsondupilumab
AT hoopesphillipc cornealrefractivesurgeryconsiderationsinpatientsondupilumab